After the recommendation of computed tomography as a routine procedure for lung cancer screening, an increasing number of young adults have been diagnosed with pulmonary ground-glass opacity (GGO). Up to 63% of pulmonary nodules with a GGO component can be malignant. Since young cancer patients have limited exposure to environmental mutagens, they have special characteristics and needs. This study sought to compare the clinicopathological characteristics of young and old patients with GGO-associated lung adenocarcinoma (GGO-LUAD). Clinicopathological data from 203 patients who underwent video-assisted thoracoscopic surgery between January 2018 and April 2020 for pulmonary GGO component nodules were reviewed. Lung nonmucinous adenocarcinoma patients younger than 40 years old and older than 40 years old were enrolled: 103 patients ≤ 40 years old and 100 patients > 40 years old. The relevant clinicopathological features, including sex, smoking status, tumor size, pathological characteristics, radiographic features and prognosis of pulmonary nodules, were evaluated. Univariate analyses were applied for comparisons between groups. The differences in baseline characteristics (sex, smoking status, tumor location) between the different age groups were not significant. Young patients were more likely to have tumors < 1 cm in size, while older patients predominantly had tumors > 2 cm in size. The mean percentage of invasive adenocarcinoma was greater in the elderly group. Young and older patients seemed to have similar subtypes of adenocarcinoma (p > 0.05) but had different degrees of differentiation (p < 0.001). The 3-year overall survival (OS) and recurrence-free survival (RFS) of the young group were 100% and 99.03%, respectively, while the 3-years OS and RFS of the older group were 99% and 98%, respectively. Our work revealed that young patients with malignant pulmonary nodules and GGOs have distinct pathological subtypes. Patients with GGOs of different ages have different clinicopathological characteristics. The 3-year prognosis of young patients with malignant pulmonary nodules with GGOs is satisfactory.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231279PMC
http://dx.doi.org/10.1038/s41598-024-66910-4DOI Listing

Publication Analysis

Top Keywords

clinicopathological features
8
young older
8
older patients
8
ground-glass opacity
8
pulmonary nodules
8
ggo component
8
young patients
8
sex smoking
8
smoking status
8
status tumor
8

Similar Publications

Background: Invasive breast cancer (BC) is a highly life-threatening disease affecting women world-wide. While its early identification may benefit the provision of more effective therapies, several BC-associated factors may influence BC patients' therapeutic outcomes. Therefore, identifying novel prognostic and therapeutic targets for invasive BC can help with accurate prognosis and therapy-related decisions.

View Article and Find Full Text PDF

Background: Pediatric nephroblastoma is the most common abdominal malignancy in children. Hyperfibrinogenemia and thrombocytosis are often associated with malignancy and poor prognosis. This study aimed to investigate the relationship between high fibrinogen and platelet levels and the clinicopathologic features as well as overall survival in pediatric nephroblastoma.

View Article and Find Full Text PDF

Background: Regulatory T cells (Tregs) play a pivotal role in the development, prognosis, and treatment of breast cancer. This study aimed to develop a Treg-associated gene signature that contributes to predict prognosis and therapy benefits in breast cancer.

Methods: Treg-associated genes were screened based on single-cell RNA-sequencing (RNA-seq) in TISCH2 database and the bulk RNA-seq in The Cancer Genome Atlas (TCGA) database.

View Article and Find Full Text PDF

Background: Bladder cancer (BCa) is one of the most common tumors of the urinary system, imposing a significant societal burden. BCa is categorized into muscle-invasive BCa (MIBC) and non-MIBC (NMIBC) types. Radical cystoprostatectomy (RCP) is the standard treatment for MIBC and refractory NMIBC, but it can lead to serious side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!